Menu
Search
|

Menu

Close
X

Jounce Therapeutics Inc JNCE.OQ (NASDAQ Stock Exchange Global Select Market)

4.51 USD
+0.11 (+2.50%)
As of 10:46 AM EST
chart
Previous Close 4.40
Open 4.47
Volume 14,291
3m Avg Volume 79,717
Today’s High 4.67
Today’s Low 4.39
52 Week High 29.02
52 Week Low 3.31
Shares Outstanding (mil) 32.63
Market Capitalization (mil) 143.56
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.50 Mean rating from 6 analysts

KEY STATS

Revenue (mm, USD)
FY18
31
FY17
72
FY16
37
FY15
0
EPS (USD)
FY18
-0.546
FY17
-0.540
FY16
-6.969
FY15
-0.733
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
29.37
Price to Sales (TTM)
vs sector
2.33
20.58
Price to Book (MRQ)
vs sector
1.32
4.23
Price to Cash Flow (TTM)
vs sector
--
21.21
Total Debt to Equity (MRQ)
vs sector
0.00
13.84
LT Debt to Equity (MRQ)
vs sector
0.00
9.93
Return on Investment (TTM)
vs sector
-14.00
13.58
Return on Equity (TTM)
vs sector
-21.77
15.11

EXECUTIVE LEADERSHIP

Richard Murray
President, Chief Executive Officer, Director, Since 2014
Salary: $500,000.00
Bonus: $250,000.00
Kimberlee Drapkin
Chief Financial Officer, Treasurer, Since 2015
Salary: $303,500.00
Bonus: $105,200.00
Hugh Cole
Chief Business Officer and Head of Corporate Development, Since 2017
Salary: $147,337.00
Bonus: $103,400.00
Elizabeth Trehu
Chief Medical Officer, Since 2015
Salary: $385,200.00
Bonus: $128,100.00
J. Duncan Higgons
Independent Director, Since 2015
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

780 Memorial Dr
CAMBRIDGE   MA   02139-4613

Phone: +1857.2593840

Jounce Therapeutics, Inc. is a clinical stage immunotherapy company. The Company is engaged in transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient. The Company’s lead product candidate, JTX-2011, is a monoclonal antibody that binds to and activates Inducible T cell CO-Stimulator (ICOS) and is in a Phase II trial.

SPONSORED STORIES